Research & Development

Can Upadacitinib Redefine the Regulatory Path for Vitiligo?
Research & Development Can Upadacitinib Redefine the Regulatory Path for Vitiligo?

Historical failures in the vitiligo pipeline, such as the cancellation of the AC##4 trial in 2016, highlight the difficulty of establishing a global site network. The recent publication of the Viti-Up Phase 3 clinical trial results in The Lancet marks a transformative moment for dermatologic

Can a Common Drug Prevent Triple-Negative Breast Cancer?
Research & Development Can a Common Drug Prevent Triple-Negative Breast Cancer?

When levels of miR-342 drop, the E2F genetic pathway is unleashed, signaling disseminated cancer cells to begin the rapid multiplication required to form tumors. This mechanism serves as a terrifying catalyst for triple-negative breast cancer, a subtype that has historically defied the precision

Michael Polansky and Outer Biosciences Use AI to Transform Skincare
Research & Development Michael Polansky and Outer Biosciences Use AI to Transform Skincare

A strategic partnership with a pharmaceutical firm allows Outer Biosciences to investigate the biological mechanisms behind skin rashes caused by cancer treatments. This initiative marks a significant departure from traditional dermatological research, signaling a move toward high-precision,

Bioengineered Conduits Show Promise for Coronary Bypass Surgery
Research & Development Bioengineered Conduits Show Promise for Coronary Bypass Surgery

A major hurdle in cardiac surgery is the compliance mismatch between stiff artificial tubes and flexible arteries, which creates turbulent blood flow and eventual graft blockage. This fundamental discrepancy has long prevented the widespread adoption of synthetic bypass grafts, as the sudden change

Will the FDA Approve Deramiocel for Duchenne Muscular Dystrophy?
Research & Development Will the FDA Approve Deramiocel for Duchenne Muscular Dystrophy?

For the 15,000 Americans living with Duchenne muscular dystrophy, the three-month regulatory delay represents a critical window where irreversible physical decline remains a constant threat. This extension, moving the target decision date from August to November 22, 2026, occurred after the Food

VA Tests Semaglutide as a New Treatment for Alcoholism
Research & Development VA Tests Semaglutide as a New Treatment for Alcoholism

VA leadership has issued a cautionary warning against the off-label use of GLP-1 medications for alcoholism without strict medical supervision and oversight. This directive arrives just as the Charles George VA Medical Center in Asheville, North Carolina, spearheads a transformative Phase 3

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later